Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00516841 · ClinicalTrials.gov registry record · Phase 2
A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer
A Phase 2 study, sponsored by Facet Biotech.
- Terminated
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT00516841 is a Phase 2 study that was terminated before completion, run by Facet Biotech. The registered enrollment target is 16 participants.
The verdict
NCT00516841, a Phase 2 study, was terminated before completion, sponsored by Facet Biotech.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
To evaluate the efficacy of voloxicimab when administered at 15 mg/kg qwk in subjects with platinum-resistant, advanced epithelial ovarian cancer or primary peritoneal cancer.
Interventions
- DRUG Volociximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2007-08 |
| Est. Completion | 2008-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00516841
The ClinicalTrials.gov registry entry for NCT00516841 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Facet Biotech, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Volociximab is the first listed.
NCT00516841 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00516841 about?
NCT00516841 is a clinical study titled "A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer". To evaluate the efficacy of voloxicimab when administered at 15 mg/kg qwk in subjects with platinum-resistant, advanced epithelial ovarian cancer or primary peritoneal cancer.
What is the current status of trial NCT00516841?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2007-08. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00516841?
The interventions under investigation include: Volociximab (DRUG).
Who is sponsoring clinical trial NCT00516841?
This trial is sponsored by Facet Biotech, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.